NDA 217188 · Pfizer
Paxlovid (Copackaged)
Nirmatrelvir, Ritonavir · Oral
NovelPriority reviewCDER novel approval, May 25, 2023: To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19
Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
May 25, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
55
13 Phase 3, 11 recruiting
FAERS reports
53,956
9,681 serious, 563 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. FDA's summary: To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 31, 2025 Supplement 8 · Efficacy · priority review LabelLetter
- May 25, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
2 products under this application
- PAXLOVID (COPACKAGED) · NIRMATRELVIR 300MG; RITONAVIR 100MG · TABLET, ORAL · Prescription
- PAXLOVID (COPACKAGED) · NIRMATRELVIR 150MG; RITONAVIR 100MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nirmatrelvir" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Pivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05041907 · 3,800 participants (planned) · Start Sep 30, 2021 · Primary completion Jan 2027
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™); Nitazoxanide and 16 more · For: COVID-19
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 7 sites in all
- A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 InfectionPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05047601 · 2,954 participants · Start Sep 9, 2021 · Primary completion Apr 12, 2022
Drug: PF-07321332; Placebo for PF-07321332 and 2 more · For: COVID-19
Sites: Pelham, Alabama; Tucson, Arizona; Fullerton, California · 170 sites in all
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialPivotal-lookingStatus unknown
University of MelbourneAcademic, hospital or other
NCT04483960 · 2,200 participants (planned) · Start Jul 28, 2020 · Primary completion Jul 25, 2025
Drug: (Arm Closed) Nafamostat Mesilate; (Arm Closed) Enoxaparin and 5 more · For: SARS-CoV-2 Infection (COVID-19)
Sites: Blacktown, Australia; Campbelltown, Australia; Darlinghurst, Australia · 25 sites in all
- EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT04960202 · 2,091 participants · Start Jul 16, 2021 · Primary completion Dec 9, 2021
Drug: PF-07321332; Ritonavir and 1 more · For: COVID-19
Sites: Pelham, Alabama; Mesa, Arizona; Tucson, Arizona · 201 sites in all
- PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in NorwayPivotal-lookingActive, not recruiting
Haukeland University HospitalAcademic, hospital or other
NCT05852873 · 2,000 participants (planned) · Start May 12, 2023 · Primary completion Sep 9, 2025
Drug: Nirmatrelvir/ritonavir; Placebo · For: Post COVID-19 Condition, Unspecified; SARS-CoV2 Infection; COVID-19
Sites: Bergen, Norway
- Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).Pivotal-lookingTerminated
PfizerPfizer (PFE)
NCT05011513 · 1,440 participants · Start Aug 25, 2021 · Primary completion Jul 25, 2022
Drug: PF-07321332; Ritonavir and 2 more · For: COVID-19
Sites: Pelham, Alabama; Mesa, Arizona; Scottsdale, Arizona · 225 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
- Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis.
Wang Y, Yang Y, Shan R, et al. · J Infect Dev Ctries 2024 · Systematic Review, Meta-Analysis
- Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
Butler CC, Pinto AD, Harris V, et al. · N Engl J Med 2026 · Clinical Trial, Phase III, Equivalence Trial
- Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
Hammond J, Fountaine RJ, Yunis C, et al. · N Engl J Med 2024 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
Hammond J, Yunis C, Fountaine RJ, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase II
- VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
Cao Z, Gao W, Bao H, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.